ModerateSelective serotonin reuptake inhibitors (SSRIs)×Essential amino acid, precursor of serotonin, melatonin and niacin. In the UK registered by MHRA as Optimax for resistant depression
Updated · Methodology
Mechanism
Escitalopram inhibits neuronal reuptake of serotonin in the central nervous system and so potentiates serotonergic activity (Lexapro label, US Food and Drug Administration, FDA). L-tryptophan is the amino acid from which the body makes serotonin, so the effects of the two substances on serotonin transmission add up. The Spanish escitalopram SmPC lists tryptophan among medicines with serotonergic effects and reports cases of potentiated effects when selective serotonin reuptake inhibitors (SSRIs) were given with tryptophan (Cipralex SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US escitalopram label includes tryptophan among the serotonergic drugs that raise the risk of serotonin syndrome (FDA). Oral L-tryptophan has no medicine label of its own in Spain or in the US.
Symptoms
The main risk of the combination is serotonin syndrome. The Spanish escitalopram SmPC reports it in rare cases in patients taking selective serotonin reuptake inhibitors (SSRIs) together with serotonergic drugs. A combination of agitation, tremor, myoclonus and hyperthermia may indicate the syndrome (Cipralex SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label adds hallucinations, delirium, coma, tachycardia, labile blood pressure, dizziness, sweating, flushing, rigidity, hyperreflexia, incoordination, seizures, nausea, vomiting and diarrhoea (Lexapro label, US Food and Drug Administration, FDA).
Management
Escitalopram is used with caution together with serotonergic medicines, tryptophan included (Cipralex SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If the combination is clinically warranted, warn the patient about the increased risk of serotonin syndrome and monitor for its signs, particularly when escitalopram is started and when the dose is increased (Lexapro label, US Food and Drug Administration, FDA). If agitation, tremor, myoclonus and hyperthermia appear, stop escitalopram and the serotonergic agent at once and start symptomatic treatment (Cipralex SmPC, AEMPS). The highlights of the US label do not recommend combining escitalopram with tryptophan. The full prescribing information advises monitoring for signs of the syndrome with tryptophan, as with other serotonergic drugs (Lexapro label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Lexapro (escitalopram) prescribing information (2023)– FDA label, Allergan, Inc., DailyMed setid 13bb8267-1cab-43e5-acae-55a4d957630a, revised 10/2023, sections 4, 5.2 and 7
- AEMPS: Ficha técnica de Cipralex 10 mg (escitalopram) (2026)– AEMPS CIMA, nregistro 65230, revisión 03/2026, secciones 4.3 y 4.5